enGene Corp (ENGN) - מקדם חוב לטווח ארוך להון

Localizing development in North America provides enGene Holdings Inc. (ENGN) with intellectual property protection and reliable access to capital. However, the company remains vulnerable to supply chain disruptions of specific components and external trade restrictions. This daily price action on GURU.Markets illustrates the trend for the asset, which has a debt-to-equity ratio of 0.14, while the business relies on joint clinical trials for bladder tumor treatments.

For enGene Holdings Inc. (ENGN), which lacks stable cash flows from finished products, the share of long-term loans within the capital structure serves as an indicator of reliance on external borrowings to sustain R&D. This metric compares liabilities with maturities exceeding one year against market capitalization, allowing investors to assess the company's financial stability and the risk of over-leverage during the early trial stages.